Yazar "Turcanu, Adela" seçeneğine göre listele

Listeleniyor 1 - 1 / 1
  • Küçük Resim
    Yayın
    The worldwide medical impact of hepatitis D virus infection: Focus to Central Asia
    (Academic Press, 2025) Aghayeva, Gulnara; Rizzetto, Mario; Örmeci, Necati; Turcanu, Adela; Abbas, Zaigham; Bedewy, Essam; Satapathy, Sanjaya K.; Al-Mahtab, Mamun; Singh, Shivaram Prasad; Akbar, Sheikh Mohammad Fazle; Ala, Aftab; Schiano, Thomas D.
    Hepatitis D virus (HDV) requires hepatitis B virus (HBV) for its replication. Concurrent infection with HBV and HDV results in more severe disease outcomes than infection with HBV alone, inducing cirrhosis, fulminant hepatitis, and hepatocellular carcinoma, and representing a significant cause of global mortality. Central Asia remains an area of high HDV prevalence but local features of the infection were poorly detailed in the past. Until recently, interferon has represented the only treatment option in patients with chronic hepatitis D; however, it is associated with low efficacy and a high burden of side effects. The discovery of the entry inhibitor bulevirtide has represented a breakthrough in HDV treatment. Other compounds (i.e., lonafarnib, new anti-hepatitis B virus drugs) are under development to provide alternative or combined strategies for HDV cure.